Premium
von Willebrand's disease in Mexico: a pilot study
Author(s) -
MajlufCruz A.,
VelezRuelas M. A.,
GonzalezAvila A. I.,
GarciaChávez J.,
Berges A.,
LopezSantiago N.,
MonroyGarcia R.,
MorenoHernandez M.,
CoronaDe La Peña N.,
AlvaradoMoreno J. A.,
IsordiaSalas I.,
Hernandez−Juarez J.
Publication year - 2013
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/hae.12016
Subject(s) - medicine , von willebrand disease , pediatrics , ecchymosis , surgery , von willebrand factor , platelet
Summary von Willebrand's disease ( VWD ) is the most commonly inherited bleeding disorder. For a long time, it has been said that VWD was absent in some countries due to ethnical differences. Information about the prevalence of VWD in Mexico remains unclear, owing largely to poor awareness and diagnosis of the disease. The aim of this study was to objectively diagnose VWD in a cohort of highly selected Mexican patients with a chronic history of bleeding. Mexican Mestizos were recruited between July 2010 and August 2011. Included were 133 adult and paediatric patients with a high suspicion of VWD . Fifty‐three were diagnosed with VWD : 47 (88.7%) with type 1 VWD , four (7.5%) with type 2a VWD and two (3.8%) with type 3 VWD . Mean age for female patients was 19.5 years (range 3–44 years) and 18.5 years (range 4–63 years) for male patients. Mean age at start of bleeding symptoms was 8.8 years (range 1–61). The most frequent clinical symptoms were epistaxis (84.9%), ecchymosis (79.2%), haematomas (71.7%), gum bleeds (62.3%) and petechia (50.9%). Severe transoperative or postoperative bleeding was found in 17 patients (32.1%). Twenty‐six women at childbearing age had a history of abnormal gynaecological bleeding. Our results clearly demonstrate the presence of VWD in Mexican and underscore the importance of a more detailed description of VWD . Efforts to increase the awareness and diagnosis of VWD could help in better identification of patients with bleeding disorders and lead to early, appropriate management with safe and efficacious therapies such as desmopressin and plasma concentrates.